Chinese General Practice ›› 2021, Vol. 24 ›› Issue (33): 4281-4286.DOI: 10.12114/j.issn.1007-9572.2021.02.024
Special Issue: 消化系统疾病最新文章合集
• Monographic Research • Previous Articles Next Articles
Published:
2021-11-20
Online:
2021-11-20
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2021.02.024
[1]中华医学会肝病学分会,中华医学会感染病学分会. 丙型肝炎防治指南(2019年版)[J]. 中华传染病杂志,2020,38(1):9-28. DOI:10.3760/cma.j.issn.1000-6680.2020.01.004. [2]ANTONELLI A,FERRI C,PAMPANA A,et al. Thyroid disorders in chronic hepatitis C[J]. Am J Med,2004,117(1):10-13. DOI:10.1016/j.amjmed.2004.01.023. [3]NAIR KESAVACHANDRAN C,HAAMANN F,NIENHAUS A. Frequency of thyroid dysfunctions during interferon alpha treatment of single and combination therapy in hepatitis C virus-infected patients:a systematic review based analysis[J]. PLoS One,2013,8(2):e55364. DOI:10.1371/journal.pone.0055364. [4]NARCISO-SCHIAVON J L,SCHIAVON L D E L. Autoantibodies in chronic hepatitis C:a clinical perspective[J]. World J Hepatol,2015,7(8):1074-1085. DOI:10.4254/wjh.v7.i8.1074. [5]MENCONI F,HASHAM A,TOMER Y. Environmental triggers of thyroiditis:hepatitis C and interferon-Α[J]. J Endocrinol Invest,2011,34(1):78-84. DOI:10.1007/bf03346699. [6]MANDAC J C,CHAUDHRY S,SHERMAN K E,et al. The clinical and physiological spectrum of interferon-alpha induced thyroiditis:toward a new classification[J]. Hepatology,2006,43(4):661-672. DOI:10.1002/hep.21146. [7]REBUFFAT S A,MORIN M,NGUYEN B,et al. Human recombinant anti-thyroperoxidase autoantibodies:in vitro cytotoxic activity on papillary thyroid cancer expressing TPO[J]. Br J Cancer,2010,102(5):852-861. DOI:10.1038/sj.bjc.6605464. [8]OPPENHEIM Y,BAN Y,TOMER Y. Interferon induced Autoimmune Thyroid Disease (AITD):a model for human autoimmunity[J]. Autoimmun Rev,2004,3(5):388-393. DOI:10.1016/j.autrev.2004.03.003. [9]PASTORE F,MARTOCCHIA A,STEFANELLI M,et al. Hepatitis C virus infection and thyroid autoimmune disorders:a model of interactions between the host and the environment[J]. World J Hepatol,2016,8(2):83-91. DOI:10.4254/wjh.v8.i2.83. [10]ANTONELLI A,FERRI C,FALLAHI P,et al. Thyroid cancer in HCV-related chronic hepatitis patients:a case-control study[J]. Thyroid,2007,17(5):447-451. DOI:10.1089/thy.2006.0194. [11]ANDRADE L J,ATTA A M,D'ALMEIDA JUNIOR A,et al. Thyroid dysfunction in hepatitis C individuals treated with interferon-alpha and ribavirin——a review[J]. Braz J Infect Dis,2008,12(2):144-148. DOI:10.1590/s1413-86702008000200009. [12]DALGARD O,BJ?RO K,HELLUM K,et al. Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha:no association with either interferon dosage or efficacy of therapy[J]. J Intern Med,2002,251(5):400-406. DOI:10.1046/j.1365-2796.2002.00974.x. [13]GROSSMAN C J,ROSELLE G A,MENDENHALL C L. Sex steroid regulation of autoimmunity[J]. J Steroid Biochem Mol Biol,1991,40(4/5/6):649-659. DOI:10.1016/0960-0760(91)90287-f. [14]JACOBSON E M,HUBER A,TOMER Y. The HLA gene complex in thyroid autoimmunity:from epidemiology to etiology[J]. J Autoimmun,2008,30(1/2):58-62. DOI:10.1016/j.jaut.2007.11.010. [15]JACOBSON E M,TOMER Y. The CD40,CTLA-4,thyroglobulin,TSH receptor,and PTPN22 gene quintet and its contribution to thyroid autoimmunity:back to the future[J]. J Autoimmun,2007,28(2/3):85-98. DOI:10.1016/j.jaut.2007.02.006. [16]BAN Y,TOZAKI T,TOBE T,et al. The regulatory T cell gene FOXP3 and genetic susceptibility to thyroid autoimmunity:an association analysis in Caucasian and Japanese cohorts[J]. J Autoimmun,2007,28(4):201-207. DOI:10.1016/j.jaut.2007.02.016. [17]ANTONELLI A,FAZZI P,FALLAHI P,et al. Prevalence of hypothyroidism and Graves disease in sarcoidosis[J]. Chest,2006,130(2):526-532. DOI:10.1378/chest.130.2.526. [18]CARACCIO N,CUCCATO S,PRATESI F,et al. Effect of type I interferon(s) on cell viability and apoptosis in primary human thyrocyte cultures[J]. Thyroid,2009,19(2):149-155. DOI:10.1089/thy.2008.0290. [19]TOMER Y,BLACKARD J T,AKENO N. Interferon alpha treatment and thyroid dysfunction[J]. Endocrinol Metab Clin North Am,2007,36(4):1051-1066;x-xi. DOI:10.1016/j.ecl.2007.07.001. [20]TRAN H A,JONES T L,GIBSON R,et al. Thyroid disease is a favorable prognostic factor in achieving sustained virologic response in chronic hepatitis C undergoing combination therapy:a nested case control study[J]. BMC Endocr Disord,2011,11:10. DOI:10.1186/1472-6823-11-10. [21]WAHID B,SHAMI K,JOIYA S A,et al. Comparing the risk of hypothyroidism in HCV patients treated with different DAA drugs combinations (sofosbuvir?+?interferon?+?ribavirin and sofosbuvir?+?daclatasvir?+?ribavirin)[J]. J Med Virol,2020. DOI:10.1002/jmv.25931. [22]YOUNOSSI Z M,KOENIG A B,ABDELATIF D,et al. Global epidemiology of nonalcoholic fatty liver disease——Meta-analytic assessment of prevalence,incidence,and outcomes[J]. Hepatology,2016,64(1):73-84. DOI:10.1002/hep.28431. [23]LUGARI S,MANTOVANI A,NASCIMBENI F,et al. Hypothyroidism and nonalcoholic fatty liver disease——a chance association?[J]. Horm Mol Biol Clin Investig,2018,41(1). DOI:10.1515/hmbci-2018-0047. [24]丁玉平,张文,夏时海,等. 非酒精性脂肪性肝病生化特点及其与相关疾病的关系[J]. 胃肠病学和肝病学杂志,2018,27(8):936-941. DOI:10.3969/j.issn.1006-5709.2018.08.023. DING Y P,ZHANG W,XIA S H,et al. Biochemical characteristics of nonalcoholic fatty liver disease and its association with other related diseases[J]. Chinese Journal of Gastroenterology and Hepatology,2018,27(8):936-941. DOI:10.3969/j.issn.1006-5709.2018.08.023. [25]谢玲玎,高燕明,卢桂芝,等. 亚临床甲状腺功能减退症与高脂血症及非酒精性脂肪肝的相关性研究[J]. 中华内分泌代谢杂志,2006,22(6):554-557. DOI:10.3760/j.issn:1000-6699.2006.06.013. XIE L D,GAO Y M,LU G Z,et al. Association of subclinical hypothyroidism with dyslipidemia and non-alcoholic fatty liver[J]. Chinese Journal of Endocrinology and Metabolism,2006,22(6):554-557. DOI:10.3760/j.issn:1000-6699.2006.06.013. [26]GUO Z,LI M,HAN B,et al. Association of non-alcoholic fatty liver disease with thyroid function:a systematic review and meta-analysis[J]. Dig Liver Dis,2018,50(11):1153-1162. DOI:10.1016/j.dld.2018.08.012. [27]LIU Y,WANG W,YU X,et al. Thyroid function and risk of non-alcoholic fatty liver disease in euthyroid subjects[J]. Ann Hepatol,2018,17(5):779-788. DOI:10.5604/01.3001.0012.3136. [28]LEE K W,BANG K B,RHEE E J,et al. Impact of hypothyroidism on the development of non-alcoholic fatty liver disease:a 4-year retrospective cohort study[J]. Clin Mol Hepatol,2015,21(4):372-378. DOI:10.3350/cmh.2015.21.4.372. [29]CHALIFOUX S L,KONYN P G,CHOI G,et al. Extrahepatic manifestations of primary biliary cholangitis[J]. Gut Liver,2017,11(6):771-780. DOI:10.5009/gnl16365. [30]MALIK R,HODGSON H. The relationship between the thyroid gland and the liver[J]. QJM,2002,95(9):559-569. DOI:10.1093/qjmed/95.9.559. [31]FLOREANI A,MANGINI C,REIG A,et al. Thyroid dysfunction in primary biliary cholangitis:a comparative study at two European centers[J]. Am J Gastroenterol,2017,112(1):114-119. DOI:10.1038/ajg.2016.479. [32]BIRó E,SZEKANECZ Z,CZIRJáK L,et al. Association of systemic and thyroid autoimmune diseases[J]. Clin Rheumatol,2006,25(2):240-245. DOI:10.1007/s10067-005-1165-y. [33]GERSHWIN M E,SELMI C,WORMAN H J,et al. Risk factors and comorbidities in primary biliary cirrhosis:a controlled interview-based study of 1032 patients[J]. Hepatology,2005,42(5):1194-1202. DOI:10.1002/hep.20907. [34]MARTíNEZ A,VARADé J,MáRQUEZ A,et al. Association of the STAT4 gene with increased susceptibility for some immune-mediated diseases[J]. Arthritis Rheum,2008,58(9):2598-2602. DOI:10.1002/art.23792. [35]KUS A,ARLUKOWICZ-GRABOWSKA M,SZYMANSKI K,et al. Genetic risk factors for autoimmune thyroid disease might affect the susceptibility to and modulate the progression of primary biliary cholangitis[J]. J Gastrointestin Liver Dis,2017,26(3):245-252. DOI:10.15403/jgld.2014.1121.263.kus. [36]中华医学会肝病学分会,中华医学会消化病学分会,中华医学会感染病学分会. 原发性胆汁性肝硬化(又名原发性胆汁性胆管炎)诊断和治疗共识(2015)[J]. 临床肝胆病杂志,2015,31(12):1980-1988. DOI:10.3969/j.issn.1001-5256.2015.12.004. [37]边新渠,陈杰,刘燕敏,等. 熊去氧胆酸治疗原发性胆汁性胆管炎患者血清甲状腺激素水平变化[J]. 实用肝脏病杂志,2019,22(5):716-719. DOI:10.3969/j.issn.1672-5069.2019.05.026. BIAN X Q,CHEN J,LIU Y M,et al. Serum thyroid hormone level changes in patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy[J]. Journal of Practical Hepatology,2019,22(5):716-719. DOI:10.3969/j.issn.1672-5069.2019.05.026. [38]JHEE J H,KIM H J,KANG W,et al. A case of autoimmune hepatitis combined with Graves' disease[J]. Taehan Sohwagi Hakhoe Chi,2015,65(1):48-51. DOI:10.4166/kjg.2015.65.1.48. [39]田佳骏,郭晓培,周璐,等. 自身免疫性肝病并发自身免疫性甲状腺病的诊治特点[J]. 中华消化杂志,2018,38(10):719-721. DOI:10.3760/cma.j.issn.0254-1432.2018.10.018. TIAN J J,GUO X P,ZHOU L,et al. Clinical characteristics of primary biliary cholangitis with thyroid disease[J]. Chin J Dig,2018,38(10):719-721. DOI:10.3760/cma.j.issn.0254-1432.2018.10.018. [40]BANO A,CHAKER L,MUKA T,et al. Thyroid function and the risk of fibrosis of the liver,heart,and lung in humans:a systematic review and meta-analysis[J]. Thyroid,2020,30(6):806-820. DOI:10.1089/thy.2019.0572. [41]VINCKEN S,REYNAERT H,SCHIETTECATTE J,et al. Liver cirrhosis and thyroid function:friend or foe? [J]. Acta Clin Belg,2017,72(2):85-90. DOI:10.1080/17843286.2016.1215641. [42]韦锦涛,陈玲玲. 代偿期乙型肝炎肝硬化患者抗病毒治疗期间甲状腺激素水平的变化[J]. 肝脏,2019,24(7):819-820. DOI:10.14000/j.cnki.issn.1008-1704.2019.07.034. •信息速递• WEI J T,CHEN L L. Changes of thyroid hormone levels during antiviral therapy in patients with compensated hepatitis B cirrhosis [J]. Chinese Hepatology,2019,24(7):819-820. DOI:10.14000/j.cnki.issn.1008-1704.2019.07.034. [43]顾薇,滕春雨. 肝硬化患者血清甲状腺激素水平变化的临床意义[J]. 中国中西医结合消化杂志,2016,24(4):275-277. DOI:10.3969/j.issn.1671-038X.2016.04.08. GU W,TENG C Y. Clinical significance of the serum thyroxin level in patients with liver cirrhosis[J]. Chinese Journal of Integrated Traditional and Western Medicine on Digestion,2016,24(4):275-277. DOI:10.3969/j.issn.1671-038X.2016.04.08. [44]ALONSO-MERINO E,MARTíN OROZCO R,RUíZ-LLORENTE L,et al. Thyroid hormones inhibit TGF-β signaling and attenuate fibrotic responses[J]. Proc Natl Acad Sci U S A,2016,113(24):E3451-3460. DOI:10.1073/pnas.1506113113. [45]WARNER M H,BECKETT G J. Mechanisms behind the non-thyroidal illness syndrome:an update[J]. J Endocrinol,2010,205(1):1-13. DOI:10.1677/JOE-09-0412. [46]俞建家,张东军,赵宏,等. 肝硬化病人下丘脑-垂体-甲状腺轴的功能变化及临床意义[J]. 安徽医药,2017,21(4):664-668. DOI:10.3969/j.issn.1009-6469.2017.04.020. YU J J,ZHANG D J,ZHAO H,et al. Functional changes and clinical significance of hypothalamic-pituitary-thyroid axis in liver cirrhotic patients[J]. Anhui Medical and Pharmaceutical Journal,2017,21(4):664-668. DOI:10.3969/j.issn.1009-6469.2017.04.020. |
[1] | YU Xueke, LI Mengling, PENG Siyuan, SHEN Yueming, LIANG Lunxi, ZENG Ya. Influence of Gastroesophageal Variceal Bleeding on One-year Mortality and Associated Factors in Patients with Liver Cirrhosis [J]. Chinese General Practice, 2023, 26(14): 1745-1752. |
[2] | WANG Xia, YANG Jinhui, ZHENG Mengyao, JIANG Ting, XU Zhiyuan, MA Honglin. Advances in Diagnostic Criteria for Acute-on-chronic Liver Failure [J]. Chinese General Practice, 2023, 26(07): 886-892. |
[3] | WANG Yingjie, CHENG Haoran, ZHOU Weihong. Correlation of Body Fat Composition and Metabolic Indicators with Metabolic-associated Fatty Liver Disease in a Non-obese Population [J]. Chinese General Practice, 2023, 26(06): 672-680. |
[4] | SHI Xuexiu, YUN Wenjing, WANG Haixu, ZHAO Yingying, YANG Yanan, SUN Tongwen. Clinical Features of Hepatic Cirrhosis in Hypopituitarism [J]. Chinese General Practice, 2023, 26(06): 699-703. |
[5] | CHEN Ran, YANG Haoran, SHI Huilian, LIU Qiong, TANG Ting. Hotspots and Trends in Research on Nutrition in Cirrhosis from 1991 to 2021: a Visualized Review [J]. Chinese General Practice, 2022, 25(32): 4091-4098. |
[6] | Ming KONG, Manman XU, Yu CHEN. Study on the Relationship between the Levels of Trace Elements and Vitamins in Peripheral Blood of Patients with End-stage Liver Disease and the Etiology and Severity of Disease [J]. Chinese General Practice, 2022, 25(12): 1455-1459. |
[7] | TIAN Caiyun,HU Han,ZHANG Guoyuan,LIN Shide. Recent Developments in the Diagnosis of Hepatogenous Diabetes [J]. Chinese General Practice, 2021, 24(9): 1158-1164. |
[8] | GUO Maodong,HU Liang,CHEN Yanping,SHI Xin,YE Xiaohua,WANG Qunying,ZHANG Yunyun,DING Jin. A Prediction Nomogram for High-risk Esophageal Varices in Cirrhosis Patients [J]. Chinese General Practice, 2021, 24(30): 3848-3855. |
[9] | LYU Yanhang,WU Shanshan,WANG Zhenchang,YE Xuejin,FU Yanqing,DUAN Guijiao,SU Xiaowen,NONG Xiaoxin. Clinical,Serum Inflammatory Cytokine,Immune,and Oxidative Stress Responses to Rougan Huaxian Granules with Transplantation of Bone Mesenchymal Stem Cells in Decompensated Cirrhosis Patients [J]. Chinese General Practice, 2021, 24(3): 355-362. |
[10] | ZHANG Guoyuan,TIAN Caiyun,HU Han,LIN Shide. Recent Progress in Immune Dysfunction of Neutrophils in Patients with Cirrhosis [J]. Chinese General Practice, 2021, 24(21): 2734-2743. |
[11] | LIN Qiuman,WANG Guiliang,QIU Ping,XU Linfang,GONG Min,HAN Ming,LI Xing,WEN Jianbo. Effects of Endoscopic Treatment Combined with Partial Splenic Artery Embolization on the Patients with Hepatic Cirrhosis Combined with Hypersplenism and Esophageal and Gastric Varices Bleeding [J]. Chinese General Practice, 2020, 23(5): 547-552. |
[12] | TANG Long,DENG Yongqiong,WANG Hong,ZHANG Zhihong,LI Xiaoming. Diagnostic Value of Noninvasive Evaluation Model of Liver Fibrosis in Chronic Hepatitis B [J]. Chinese General Practice, 2020, 23(27): 3408-3415. |
[13] | ZHANG Yan*,FAN Xiaoxiang,ZHANG Meiwu,ZHUANG Luhui,MAO Dafeng. Role of NLRC5 in the Activation of Hepatic Stellate Cells Induced by TGF-β1 and Reversal of Hepatic Fibrosis [J]. Chinese General Practice, 2020, 23(24): 3051-3059. |
[14] | ZHAO Yang,LI Ye,ZHAO Chen. Efficacy Analysis of Tenofovir on HBV-related Decompensated Liver Cirrhosis Patients Experiencing Antiviral Treatment Failure [J]. Chinese General Practice, 2020, 23(2): 165-169. |
[15] | GUO Chunmei,WU Jing,YIN Jinshu,GE Hui. Value of FIB-4 Index and Liver Stiffness Measurement in the Assessment of Significant Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease with Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2019, 22(9): 1009-1013. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||